Old Articles: <Older 8421-8430 Newer> |
|
Pharmaceutical Executive September 1, 2012 Thomas Baker |
The Big Sell: Biologics In Emerging Markets High priced biologics may have a bright future in emerging markets, but winning access in the short term will be a hard sell without a tailored clinical profile, a compelling local message, and direct government support. |
Pharmaceutical Executive September 1, 2012 Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive September 1, 2012 Bill Trombetta |
Pharm Exec's 11th Annual Industry Audit: Busting the Tape With pharmaceuticals are eyed as a commodity purchase, those traditional high margins are getting harder to find. Shareholder value and profits now depends on finding pockets of "good" growth, in segments with long-term potential in serving an unmet medical need, with fewer players. |
Pharmaceutical Executive September 1, 2012 Ben Comer |
You Tell Me Specialized knowledge about disease and treatment is no longer the exclusive province of practicing physicians. For biopharmaceutical manufacturers, patient feedback can help to elucidate an unmet need. |
Pharmaceutical Executive September 1, 2012 |
Patients Wade Into the Pricing Debate Europe's fiscal crisis is becoming a new rallying cry for patient groups, but regional unity is still elusive. |
Pharmaceutical Executive September 1, 2012 Robin Hertz |
The Endless Treadmill of End-of-Life Care Bending the cost curve back to valuing the cycle of life. |
Pharmaceutical Executive September 1, 2012 Roy F. Waldron |
Open Innovation in Pharma: Defining the Dialogue There is much talk today about "open innovation" in business and research forums, but what exactly does it mean? How does open innovation as a concept apply to the pharmaceutical sector? |
Pharmaceutical Executive September 1, 2012 Jill Wechsler |
Costs, Coverage, and Court Decisions Its election season and drug pricing issues are once again front and center in the policy wars on managing the high cost of healthcare. |
Pharmaceutical Executive September 1, 2012 Al Topin |
Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty. |
Pharmaceutical Executive September 1, 2012 William Looney |
The Margin Call Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns. |
<Older 8421-8430 Newer> Return to current articles. |